Rustad, Andrea M.
Nickles, Melissa A.
Bilimoria, Sara N.
Lio, Peter A. http://orcid.org/0000-0001-7600-0152
Article History
Accepted: 6 October 2021
First Online: 23 October 2021
Declarations
:
: No funding sources were secured for this study.
: Dr. Lio reports research grants/funding from the National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie; is on the speaker’s bureau for Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, and L’Oreal; and reports consulting/advisory boards for Almirall, ASLAN Pharmaceuticals, Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO Pharmaceuticals, AbbVie, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs (stock options), Galderma, Amyris, Bodewell, and My-Or Diagnostics. The other authors report no conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: PL conceived the research idea. AR, MN, and SB researched and wrote the article with input and editing from PL.